Lexette® Foam (halobetasol propionate)

For adults with plaque psoriasisDiscover LEXETTE Foam: The first and only halobetasol propionate, 0.05% in a foam vehicle

Lexette Foam provides the convenience patients want and the strength they need¹

Elegant and clean
foam vehicle
Powerful efficacy
with fast results
Easy to apply for
up to 2 weeks
Co-pay options
for easier access
Supplied in 50-gram cans

Plaque psoriasis Patients agree that the vehicle matters

Watch actual patients, in their own words, discuss their frustrations with other vehicles.

Nearly 8 in 10 patients stated that not feeling greasy or sticky is extremely important when using their topical psoriasis treatment.*²

*135 patients with plaque psoriasis were asked to rate the acceptability of product administration and overall treatment experience by answering questions from a survey.²

Lexette Foam has what patients look for when treating plaque psoriasis¹

Not greasy or sticky
Dries quickly
Leaves no residue
Easy to apply and spread
Maintains consistency
Lightweight and airy
Free of fragrances and parabens

Take a closer look at the formulation

Excellent access and affordability

The Mayne Pharma Patient Savings Program helps patients save on LEXETTE Foam.

See the Mayne Pharma Patient Savings Program

Powerful efficacy. fast results.

Up to 5x more patients achieved Treatment Success vs vehicle foam in 2 weeks in combined studies of adults with moderate to severe plaque psoriasis involving 2%–12% body surface area.¹

Review the clinical data

Treatment Success was defined as an IGA score of clear or almost clear and a 2-grade IGA improvement compared to vehicle foam at 2 weeks.

Request a visit from a rep

Get samples and learn more about LEXETTE Foam.

Request now

PROVEN tolerability and safety profile through Week 2¹

Review the profile

Take a look at another foam for plaque psoriasis from Mayne Pharma >

Indication

LEXETTE^® Foam (halobetasol propionate) is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients 12 years and older.

Important Safety Information

LEXETTE^® Foam (halobetasol propionate) is a topical corticosteroid that has been shown to suppress the hypothalamic-pituitary-adrenal (HPA) axis.

Systemic effects of topical corticosteroids may include reversible HPA axis suppression, with the potential for glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of treatment of the topical corticosteroid.

The potential for hypothalamic-pituitary adrenal (HPA) suppression with LEXETTE Foam was evaluated in a study of 25 adult subjects with moderate to severe plaque psoriasis involving ≥15% of their body surface area. LEXETTE Foam produced laboratory evidence of HPA axis suppression when used twice daily for two weeks in 6 out of 25 (24%) adult subjects with plaque psoriasis. Recovery of HPA axis function was generally prompt with the discontinuation of treatment.

Systemic effects of topical corticosteroids may also include Cushing's syndrome, hyperglycemia, and glucosuria. Use of more than one corticosteroid-containing product at the same time may increase the total systemic exposure to topical corticosteroids.

Local adverse reactions from topical corticosteroids may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria. These may be more likely to occur with occlusive use, prolonged use, or use of higher potency corticosteroids, including LEXETTE Foam.

Some local adverse reactions may be irreversible. Use of topical corticosteroids may increase the risk of posterior subcapsular cataracts and glaucoma.

To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.